FrancophonIA/ELRC3.0 huggingface dataset:
English: - if you get left upper belly (abdominal) pain, pain below the left rib cage or pain at the tip of your shoulder, as there may be a problem with your spleen (enlargement of the spleen (splenomegaly) or rupture of the spleen).
Croatian: - ako osjetite bol u gornjem lijevom dijelu trbuha (abdomena), bol ispod lijevog prsnog koša ili bol pri vrhu ramena jer možda imate problem sa slezenom (uvećanje slezene (splenomegalija) ili puknuće (ruptura) slezene).
English: • redness of the skin (erythema)
Croatian: • crvenilo kože (eritem)
English: Please tell your doctor before starting treatment if you have: - sickle cell anaemia, as Nivestim may cause sickle cell crisis.
Croatian: Recite svom liječniku prije početka liječenja ako imate: anemiju srpastih stanica jer
English: Special care should be taken in the diagnosis of SCNs to distinguish them from other haematopoietic disorders such as aplastic anaemia, myelodysplasia, and myeloid leukaemia.
Croatian: Pri dijagnosticiranju SCN-ova nužan je poseban oprez kako bi ih se razlikovalo od drugih hematopoetskih poremećaja poput aplastične anemije, mijelodisplazije i mijeloične leukemije.
English: • high blood pressure (hypertension)
Croatian: • visok krvni tlak (hipertenzija)
English: In patients receiving cytotoxic chemotherapy, a transient increase in neutrophil counts is typically seen 1 to 2 days after initiation of filgrastim therapy.
Croatian: U bolesnika koji primaju citotoksičnu kemoterapiju, prolazni porast broja neutrofila tipično nastupa 1 do 2 dana nakon početka liječenja filgrastimom.
English: Sweets syndrome (acute febrile neutrophilic dermatosis)
Croatian: Kutani vaskulitis Sweetov sindrom (akutna febrilna neutrofilna dermatoza)
English: Studies of filgrastim in patients with severe impairment of renal or hepatic function demonstrate that it exhibits a similar pharmacokinetic and pharmacodynamic profile to that seen in normal individuals.
Croatian: Ispitivanja filgrastima u bolesnika s teškim oštećenjem bubrega ili jetre pokazuju sličan farmakokinetički i farmakodinamički profil kao i u zdravih osoba.
English: Neutrophil count
Croatian: Broj neutrofila
English: The recommended starting dose of filgrastim is 0.1 MU (1 µg)/kg/day with titration up to a maximum of 0.4 MU (4 µg)/kg/day until a normal neutrophil count is reached and can be maintained (ANC > 2.0 x 10
Croatian: Preporučena početna doza filgrastima je 0,1 MU (1 µg)/kg/dan i može se povisiti do najviše 0,4 MU (4 µg)/kg/dan, do postizanja normalnog broja neutrofila koji će biti moguće održavati (ABN > 2,0 x 9/l).
English: If you develop or are likely to develop cancers of the blood, you should not use Nivestim, unless instructed by your doctor.
Croatian: Ako razvijete ili ste skloni razvoju raka krvi, ne smijete primjenjivati
English: • swelling in the hands and feet (oedema peripheral)
Croatian: • oticanje šaka i stopala (periferni edem)
English: Diluted filgrastim may be adsorbed to glass and plastic materials unless it is diluted in 5% glucose solution (see section 6.6).
Croatian: Razrijeđeni filgrastim se može adsorbirati na staklene i plastične materijale ako nije razrijeđen u 5%-tnoj otopini glukoze (vidjeti dio 6.6).
English: • low blood pressure (hypotension)
Croatian: • nizak krvni tlak (hipotenzija)
English: Regular urinalysis should be performed to monitor these events.
Croatian: Te događaje treba nadzirati redovitim pretragama urina.
English: The first dose of filgrastim should be administered at least 24 hours after cytotoxic chemotherapy.
Croatian: Prvu dozu filgrastima potrebno je primijeniti najmanje 24 sata nakon citotoksične kemoterapije.
English: A subset of approximately 12% of patients who had normal cytogenetic evaluations at baseline were subsequently found to have abnormalities, including monosomy 7, on routine repeat evaluation.
Croatian: U oko 12% bolesnika s urednim citogenetskim nalazom prije početka primjene lijeka kasnije su, pri rutinskim kontrolama nađene abnormalnosti, uključujući monosomiju
English: Discontinuation of filgrastim therapy usually results in a 50% decrease in circulating neutrophils within 1 to 2 days, with a return to normal levels in 1 to 7 days.
Croatian: Prekid terapije filgrastimom obično dovodi do 50%tnog smanjenja broja cirkulirajućih neutrofila u roku od 1 do 2 dana, koji se normalizira nakon 1 do 7 dana.
English: After dilution: Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2 °C to 8 °C.
Croatian: Nakon razrjeđenja: Pokazalo se da je razrijeđena otopina za infuziju kemijski i fizikalno stabilna tijekom 24 sata na temperaturi od 2 °C do 8 °C.
English: A randomised, open-label, single-dose, comparator-controlled, two-way crossover study in 46 healthy volunteers showed that the pharmacokinetic profile of Nivestim was comparable to that of the reference product after subcutaneous and intravenous administration.
Croatian: Randomizirano, otvoreno, dvosmjerno ukriženo ispitivanje jedne doze kontrolirano komparatorom koje je uključivalo 46 zdravih ispitanika pokazalo je da Nivestim ima usporedivi farmakokinetički profil s profilom referentnog lijeka nakon supkutane i intravenske primjene.
English: The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.
Croatian: Sigurnost i djelotvornost primjene filgrastima slični su u odraslih i u djece koja primaju citotoksičnu kemoterapiju.
English: Filgrastim may be given as a 24 hour subcutaneous continuous infusion or subcutaneous injection.
Croatian: Filgrastim se može davati kao 24-satna supkutana infuzija ili supkutana injekcija.
English: The mechanism of vasculitis in patients receiving filgrastim is unknown.
Croatian: Mehanizam pojave vaskulitisa u bolesnika koji su primali filgrastim nije poznat.
English: Mobilisation of PBPC does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.
Croatian: Zdravi davatelj nema izravne kliničke koristi od mobilizacije KMSPK te o tom postupku treba razmišljati samo u svrhu alogenog presađivanja matičnih stanica.
English: The recommended dose of filgrastim for PBPC mobilisation after myelosuppressive chemotherapy is 0.5 MU (5 µg)/kg/day from the first day after completion of chemotherapy until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range.
Croatian: Preporučena doza filgrastima za mobilizaciju KMSPK nakon mijelosupresivne kemoterapije je 0,5 MU (5 µg)/kg/dan, od prvog dana nakon završetka kemoterapije do prolaska očekivanog najnižeg broja neutrofila i do normalizacije njihovog broja.
English: This reduces the ability of your blood to clot (thrombocytopenia).
Croatian: To stanje smanjuje sposobnost zgrušavanja krvi (trombocitopenija).
English: In order to determine a patient's trough or nadir ANC, it is recommended that blood samples are taken for ANC measurement immediately prior to any scheduled dosing with filgrastim.
Croatian: Da bi se odredio stvarni ili pak najmanji ukupni broj neutrofila, preporučuje se uzorke krvi za to određivanje uzimati neposredno prije svake predviđene primjene filgrastima.
English: You will need to take Nivestim until your white blood cell count is normal.
Croatian: Nivestim ćete morati uzimati dok se broj Vaših leukocita ne vrati u normalu.
English: Donors who receive G-CSFs for PBPC mobilisation should be monitored until haematological indices return to normal.
Croatian: Davatelje koji primaju čimbenik G-CSF radi mobilizacije krvotvornih matičnih stanica periferne krvi treba nadzirati sve dok se hematološki pokazatelji ne normaliziraju.
English: Initial dose adjustment to alternate day dosing with 30 MU (300 µg)/day is recommended.
Croatian: Preporučuje se početno prilagođavanje početne doze na 30 MU (300 µg)/dan, svaki drugi dan.
English: - if you have any of the following or combination of the following side effects: o swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness.
Croatian: - ako imate bilo koju od sljedećih nuspojava ili kombinaciju sljedećih nuspojava: o oticanje ili podbuhlost, što može biti povezano sa smanjenom učestalošću mokrenja, otežano disanje, natečenost trbuha i osjećaj punoće te opći osjećaj umora.
English: Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy suggesting no age-related differences in the pharmacokinetics of filgrastim.
Croatian: Podaci iz kliničkih ispitivanja pedijatrijskih bolesnika ukazuju da su sigurnost i djelotvornost filgrastima slične u odraslih i djece koji primaju citotoksičnu kemoterapiju, što upućuje na to da razlike u farmakokinetici filgrastima nisu povezane sa dobi.
English: Injection site reaction
Croatian: Reakcija na mjestu injekcije
English: Do not use this medicine after the expiry date which is stated on the outer carton and on the pre-filled syringe after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na vanjskom pakiranju i napunjenoj štrcaljki iza oznake „Rok valjanosti“ ili kratice EXP.
English: As a result of the potential to receive higher doses or a greater number of these medications with filgrastim therapy, the patient may be at higher risk of developing thrombocytopenia and anaemia.
Croatian: Zbog mogućnosti da se pri primjeni filgrastima primijene više doze i veći broj lijekova, bolesnik može biti izložen većem riziku od trombocitopenije i anemije.
English: cells/kg recipient bodyweight.
Croatian: + stanica/kg tjelesne težine primatelja.
English: Nivestim is a clear colourless solution for injection/infusion in a glass pre-filled syringe with an injection needle (stainless steel) with a needle guard.
Croatian: Nivestim je bistra bezbojna otopina za injekciju/infuziju u napunjenoj staklenoj štrcaljki s iglom za injekciju (od nehrđajućeg čelika) i štitnikom za iglu.
English: Recipients of allogeneic PBPCs mobilised with filgrastim experienced significantly more rapid haematological recovery, leading to a significant decrease in time to unsupported platelet recovery when compared with allogeneic bone marrow transplantation.
Croatian: U primatelja alogenih KMSPK-ova mobiliziranih filgrastimom značajno brže nastupa hematološki oporavak, čime se u usporedbi s presađivanjem koštane srži, značajno skraćuje vrijeme do oporavka trombocita bez primijenjene potpore.
English: Acetic acid glacial, sodium hydroxide, polysorbate 80, sorbitol (E420) and water for injections..
Croatian: Acetatna kiselina, ledena, natrijev hidroksid, polisorbat 80, sorbitol (E420) i voda za injekciju.
English: Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 to 2 days, and to normal levels within 1 to 7 days.
Croatian: Nakon prestanka primjene filgrastima, broj neutrofila u perifernoj krvi smanji se za 50% u roku od 1 do 2 dana, a na normalne vrijednosti vrati se u roku od 1 do 7 dana.
English: Another randomised, double-blind, multiple-dose, comparator-controlled, two-way crossover study in 50 healthy volunteers showed that the pharmacokinetic profile of Nivestim was comparable to that of the reference product after subcutaneous administration.
Croatian: Drugo randomizirano, dvostruko slijepo, dvosmjerno ukriženo ispitivanje višestrukih doza kontrolirano komparatorom koje je uključivalo 50 zdravih ispitanika pokazalo je da Nivestim ima farmakokinetički profil usporediv s profilom referentnog lijeka nakon supkutane primjene.
English: Filgrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
Croatian: Filgrastim je indiciran za skraćivanje vremena trajanja neutropenije i smanjenje incidencije febrilne neutropenije u bolesnika s malignom bolesti (osim kronične mijeloične leukemije i mijelodisplastičkih sindroma) koji se liječe standardnom citotoksičnom kemoterapijom i za skraćenje trajanja neutropenije u bolesnika koji su na mijeloablativnoj terapiji koja prethodi presađivanju koštane srži za koje se smatra da imaju povećan rizik od razvoja produljene teške neutropenije.
English: Reversal of neutropenia or maintaining normal neutrophil counts: filgrastim should be given by subcutaneous injection.
Croatian: Promjena u liječenju neutropenije ili održavanju normalne razine neutrofila: filgrastim treba davati supkutanom injekcijom.
English: Filgrastim acts primarily on neutrophil precursors to exert its effect in elevating neutrophil counts.
Croatian: Filgrastim djeluje prvenstveno na preteče neutrofila, povećavajući tako broj neutrofila.
English: In clinical studies and the post-marketing setting pulmonary adverse effects including interstitial lung disease, pulmonary oedema, and lung infiltration have been reported in some cases with an outcome of respiratory failure or acute respiratory distress syndrome (ARDS), which may be fatal (see section
Croatian: U kliničkim ispitivanjima te nakon stavljanja lijeka u promet, u nekim su slučajevima prijavljene plućne nuspojave, uključujući intersticijsku bolest pluća, plućni edem i plućne infiltracije s posljedičnim zatajenjem disanja ili sindromom akutnog respiratornog distresa (ARDS), koji mogu imati smrtni ishod (vidjeti dio 4.4).
English: How to store Nivestim
Croatian: Kako čuvati Nivestim
English: The effects of filgrastim on neutropenia due to bone marrow infiltrating infection or malignancy have not been well established.
Croatian: Učinci filgrastima na neutropeniju čiji je uzrok infiltracija koštane srži infektom ili zloćudnom bolešću nisu ispitani.
English: Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2°C to 8°C.
Croatian: Nakon razrjeđivanja lijeka dokazana je kemijska i fizikalna stabilnost razrijeđene otopine za infuziju tijekom 24 sata pri temperaturi od 2°C do 8°C.
English: For patients treated with filgrastim diluted to concentrations below 1.5 MU (15 µg) per ml, human serum albumin (HSA) should be added to a final concentration of 2 mg/ml.
Croatian: Za bolesnike koji su liječeni filgrastimom razrijeđenim na koncentracije niže od 1,5 MU (15 g) po mililitru, treba dodati ljudski serumski albumin (HSA) dok se ne postigne koncentracija od 2 mg/ml.
English: • Keep used syringes out of the reach and sight of children
Croatian: • Iskorištene štrcaljke čuvajte izvan dohvata i pogleda djece.
English: Therefore, in patients with reduced precursors neutrophil response may be diminished (such as those treated with extensive radiotherapy or chemotherapy, or those with bone marrow infiltration by tumour).
Croatian: Stoga u bolesnika sa smanjenim brojem preteča neutrofila, odgovor u smislu povećanja broja neutrofila može biti slabiji (npr. u liječenih opsežnom radioterapijom ili kemoterapijom te onih s tumorskom infiltracijom koštane srži).
English: The dosage recommendations in paediatric patients are the same as those in adults receiving myelosuppressive cytotoxic chemotherapy.
Croatian: Preporuke o doziranju u pedijatrijskih bolesnika jednake su onima za odrasle na mijelosupresivnoj citotoksičnoj kemoterapiji.
English: For PBPC mobilisation in normal donors, filgrastim should be administered at 1.0 MU (10 µg)/kg/day for 4 to 5 consecutive days.
Croatian: Za mobilizaciju KMSPK u zdravih davatelja, filgrastim treba davati u dozi od 1,0 MU (10 µg)/kg/dan putem tijekom 4 do 5 uzastopnih dana.
English: Special precautions in cancer patients
Croatian: Posebne mjere opreza u bolesnika oboljelih od raka
English: • soreness and swelling of the digestive tract lining which runs from the mouth to the anus
Croatian: • bolnost i oticanje sluznice probavnog trakta koja ide od usta do čmara (upala sluznice)
English: Treatment with filgrastim significantly reduces the durations of febrile neutropenia, antibiotic use and hospitalisation after induction chemotherapy for acute myelogenous leukaemia or myeloablative therapy followed by bone marrow transplantation.
Croatian: Primjenom filgrastima značajno se skraćuju trajanja febrilne neutropenije, vrijeme primjene antibiotika i trajanje hospitalizacije nakon indukcijske kemoterapije zbog akutne mijeloične leukemije ili mijeloablativne terapije prije presađivanja koštane srži.
English: • The other ingredients are acetic acid (glacial), sodium hydroxide, sorbitol E420, polysorbate 80, and water for injections.
Croatian: • Pomoćne tvari su ledena acetatna kiselina, natrijev hidroksid, sorbitol (E420), polisorbat 80 i voda za injekciju.
English: Dizziness may occur following the administration of filgrastim (see section 4.8).
Croatian: Nakon primjene filgrastima može se pojaviti omaglica (vidjeti dio 4.8).
English: The results of flow cytometric analysis of CD34
Croatian: Rezultati analize broja CD34
English: Paediatric use in the SCN and cancer settings
Croatian: Pedijatrijska primjena u bolesnika sa SCN-om i oboljelih od raka
English: • severe pain in the bones, chest, gut or joints (sickle cell anaemia with crisis)
Croatian: • jaka bol u kostima, prsnom košu, želucu ili zglobovima (anemija srpastih stanica s krizom)
English: However, in view of the potential risks associated with severe leucocytosis, a white blood cell count should be performed at regular intervals during filgrastim therapy.
Croatian: No, sa stajališta mogućih rizika povezanih s teškom leukocitozom, pri liječenju filgrastimom valja redovito, u određenim vremenskim razmacima, provjeravati broj leukocita.
English: The recommended starting dose of filgrastim is 1.0 MU (10 µg)/kg/day.
Croatian: Preporučena početna doza filgrastima je 1,0 MU (10 µg)/kg/dan.
English: There are no or limited amount of data from the use of filgrastim in pregnant women.
Croatian: Nema podataka ili su podaci o primjeni filgrastima u trudnica ograničeni.
English: Nivestim is a biosimilar medicinal product.
Croatian: Nivestim je biosličan lijek.
English: There have been reports of graft versus host disease (GvHD) and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see sections 4.8 and 5.1).
Croatian: Postoje izvještaji o bolesti presatka protiv primatelja GvHD (engl. graft versus host disease) kao i smrtni ishodi u bolesnika koji su nakon alogene transplantacije koštane srži dobivali G-CSF (vidjeti dijelove 4.8 i 5.1).
English: The effects of filgrastim in patients with substantially reduced myeloid progenitors have not been studied.
Croatian: Učinci filgrastima u bolesnika sa znatno smanjenim brojem krvotvornih matičnih stanica nisu ispitivani.
English: PBPC mobilisation should be considered only in donors who meet normal clinical and laboratory eligibility criteria for stem cell donation with special attention to haematological values and infectious disease.
Croatian: Mobilizaciju KMSPK valja razmatrati samo u davatelja koji zadovoljavaju uobičajene kliničke i laboratorijske kriterije prikladnosti za donaciju matičnih stanica.
English: Please tell your doctor immediately during treatment: - if you experience an allergic reaction including weakness, drop in blood pressure, difficulty breathing, swelling of the face (anaphylaxis), skin rash, itchy rash (urticaria), swelling of the face, lips, mouth, tongue or throat (angioedema) and shortness of breath (dyspnoea).
Croatian: Odmah recite liječniku tijekom liječenja: - ako iskusite alergijsku reakciju uključujući slabost, pad krvnog tlaka, poteškoće u disanju, oticanje lica (anafilaksija), osip na koži, svrbljivi osip (urtikarija), oticanje lica, usana, usta, jezika ili grla (angioedem) i zadihanost (dispneja). - ako iskusite kašalj, vrućicu i poteškoće u disanju (dispneja) jer to mogu biti znakovi akutnog sindroma respiratornog distresa (ARDS). - ako iskusite ozljedu bubrega (glomerulonefritis).
English: • injection site reaction
Croatian: • reakcija na mjestu ubrizgavanja
English: Do not try to replace the protective cap.
Croatian: Nemojte vraćati zaštitnu kapicu na iglu.
English: Very common
Croatian: Nuspojave Vrlo često
English: Vomiting a,e
Croatian: Povraćanje a,e
English: Each ml contains 60 million units [MU] (600 g) or 96 million units [MU] (960 g) of filgrastim.
Croatian: Jedan ml otopine sadrži 60 milijuna jedinica [MU] (600 g) ili 96 milijuna jedinica [MU] (960 g) filgrastima.
English: Use of Active UltraSafe Needle Guard for Nivestim 12 MU/0.2 ml solution for injection/infusion
Croatian: Uporaba aktivnog ultrasigurnog štitnika igle za Nivestim 12 MU/0,2 ml otopinu za injekciju/infuziju
English: Common (≥ 1/100 to
Croatian: Često (≥ 1/100 i < 1/10)
English: Detailed information is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Croatian: Detaljne informacije dostupne su na internetskoj stranici Europske agencije za lijekove (EMA) http://www.ema.europa.eu.
English: Rare (≥ 1/10,000 to
Croatian: Rijetko (≥ 1/10 000 i
English: • inflammation of the lungs (interstitial lung disease)
Croatian: • upala pluća (intersticijska plućna bolest)
English: Kidney injury has been seen in patients who received filgrastim.
Croatian: Ozljeda bubrega primijećena je u bolesnika koji su primili filgrastim.
English: The recommended dose of filgrastim is 0.5 MU (5 µg)/kg/day.
Croatian: Preporučena doza filgrastima je 0,5 MU (5 µg)/kg/dan.
English: The first dose of filgrastim should be administered at least 24 hours following cytotoxic chemotherapy and at least 24 hours after bone marrow infusion.
Croatian: Prvu dozu filgrastima treba dati najmanje 24 sata nakon citotoksične kemoterapije i najmanje 24 sata nakon infuzije koštane srži.
English: Adverse events with higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy.
Croatian: Štetni događaji veće incidencije u bolesnika liječenih filgrastimom nego u onih koji su primali placebo, te povezane s posljedicama podležeće zloćudne bolesti ili citotoksične kemoterapije.
English: The most commonly reported adverse reactions are pyrexia, musculoskeletal pain (which includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain), anaemia, vomiting, and nausea.
Croatian: Najčešće zabilježene nuspojave su pireksija, mišićno-koštana bol (koja uključuje bol u kostima, bol u leđima, artralgiju, mialgiju, bol u ekstremitetima, bol u mišićima i kostima, bol u mišićima i kostima prsnog koša, bol u vratu), anemija, povraćanje i mučnina.
English: In clinical trials, 97% of patients who responded had a complete response at doses ≤ 24 µg/kg/day.
Croatian: U kliničkim je ispitivanjima kompletan odgovor postignut pri dozi od  24 µg/kg/dan u 97% ispitanika koji su odgovorili na terapiju.
English: It is recommended to perform morphologic and cytogenetic bone marrow examinations in patients at regular intervals (approximately every 12 months).
Croatian: Preporučuje se u bolesnika u pravilnim vremenskim razmacima (približno svakih 12 mjeseci) obavljati morfološke i citogenetske pretrage koštane srži.
English: Pulmonary adverse events
Croatian: Plućni štetni događaji
English: Special precautions in recipients of allogeneic PBPCs mobilised with filgrastim
Croatian: Posebne mjere opreza u primatelja alogenih KMSPK-ova mobiliziranih filgrastimom
English: Haematuria was common and proteinuria occurred in a small number of patients.
Croatian: U malog broja bolesnika javila se proteinurija, a hematurija je bila česta.
English: These autologous PBPCs may be harvested and infused after high dose cytotoxic therapy, either in place of, or in addition to bone marrow transplantation.
Croatian: Autologne KMSPK mogu se izdvojiti i ponovno dati infuzijom nakon visokodozne citotoksične terapije, bilo umjesto presađivanja koštane srži, bilo zajedno s njim.